About us
Here you will find more information about the Lundberg Laboratory for diabetes research, our goals, collaborations, and our research environment.
The Lundberg Laboratory for diabetes research was established in the mid-1990s with donations from the IngaBritt and Arne Lundberg Research Foundation. Diabetes is the number one cause for severe kidney disease. The desire of the foundation was, and still is, to support research aiming to prevent diabetes and its serious complications. The Lundberg Laboratory is a part of the Institute of Medicine at the University of Gothenburg.
Our research
Research at the Lundberg Laboratory is focused on understanding the causes of type 2 diabetes and insulin resistance. Here we conduct both basic and clinical research, including testing new medicines. By examining individuals with hereditary risks for developing type 2 diabetes we are able to gain insight into early genetic alterations that precedes the development of type 2 diabetes.
Our goals
We aim to
- identify early risk factors for developing type 2 diabetes
- understand and identify biomarkers to enable early intervention, including how to prevent individuals from developing type 2 diabetes
- understand the interaction between factors such as age, overweight and obesity and the development of insulin resistance
- understand the impact of increased adipose tissue mass
- understand the role of cellular senescence (cessation of cell division), which has been shown to be increased in individuals with type 2 diabetes and in individuals with hereditary risks for developing diabetes
Close collaboration with medical services
The Lundberg Laboratory is a translational research environment with close collaboration between basic and clinical researchers. Located within the Sahlgrenska University Hospital, Gothenburg, Sweden, our position facilitates collaboration with medical and healthcare experts, both at the hospital and at Diabetescentrum (the Centre for Diabetes). We conduct basic research on molecular mechanisms of disease development, and clinical research on metabolism in individuals with high risks of developing type 2 diabetes, as well as determining the efficacy of new medicines.
Collaboration with the pharmaceutical industry
Our researchers collaborate with investigators within the pharmaceutical industry, including Astra Zeneca and Novo Nordisk. These collaborations enable early testing of drug discoveries in both cell and animal models. We also work together to examine new mechanisms of type 2 diabetes and insulin resistance, and how they can contribute to the development of new treatments.
Join us
Are you a researcher wishing to move on to the next stage of your career? We offer outstanding research environments in which you can develop your skills. Work under way at the Institute includes preclinical research in a laboratory environment, clinical research and studies at population level. We cooperate closely with healthcare providers, have a large international network of contacts and are also connected with Core Facilities that provide advanced technical infrastructure and skills for every researcher.
Read more about why should join us
